SavedAdd your journal

Journals / Göztepe Tıp Dergisi / 2010 / Cilt: 25 - Sayı: 3

Rifampycine induced trombositopenia: A case report

Rifampisine bağlı trombositopeni

Hamdiye TURAN
Abdurrahman ABAKAY
Abdullah Çetin TANRIKULU
Pages
142–144
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients who had taken anti-TB treatment this complication to retain and should be follow.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tuberculosis (TB) is still remained serious public health problem.
📊
Key Findings & Data:This complication is rare when the medication is given in small daily doses (10 mg/kg). 16 years old man case with anti- TB is given daily doses (10 mg/kg) but to develop this complication is reported.
💡
Conclusion & Impact:Patients who had taken anti-TB treatment this complication to retain and should be follow.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Tuberculosis (TB) is still remained serious public health problem. Anti-TB treatment is given twice weekly caused by immun thrombocytopenia. This complication is rare when the medication is given in small daily doses (10 mg/kg). 16 years old man case with anti- TB is given daily doses (10 mg/kg) but to develop this complication is reported. This patient had applied to emergency service with epistaksis and is administered symptomatic therapy. Patients who had taken anti-TB treatment this complication to retain and should be follow.

🔖

Cite This Article

TURAN, H., ABAKAY, A., TANRIKULU, A. Ç. (2022). Rifampycine induced trombositopenia: A case report. Göztepe Tıp Dergisi, Cilt: 25 - Sayı: 3, 142–144. https://ajindex.com/articles/526187

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Çiftçi B, Güler ZM, Yılmaz A, Özyılmaz E, Demirağ F, Erdoğan Y. Tüberkülozlu hastalarda trombositopeni, farklı klinik seyirli üç olgu. Solunum hastalıkları dergisi 2004; 15(4):190-194
  2. Blajchman MA, Lowry RC, Pettit JE, Stradling P. Rifampicin-induced immune thrombocytopenia. Br Med J 1970 4; 3(5713):24-6
  3. Hadfield JW. Rifampicin-induced thrombocytopenia. Postgrad Med J 1980; 56(651):59-60
  4. Mehta YS, Jijina FF, Badakere SS, Pathare AV, Mohanty D. Rifampicin-induced immune thrombocytopenia. Tuber Lung Dis 1996; 77(6):558-62
  5. Garg R, Gupta V, Mehra S, Singh R, Prasad R. Rifampicin induced thrombocytopenia. Indian J Tuberc 2007; 54(2):94-6
  6. Lee CH, Lee CJ. Thrombocytopenia--a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. Chest 1989; 96(1):202-3
  7. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3:160-74
  8. Pau AK, Fisher MA. Severe thrombocytopenia associated with once-daily rifampin therapy. Drug Intell Clin Pharm 1987; 21(11):882-4
  9. Poole G, Stradling P, Worlledge S. Potentially serious side-effects of high-dose twice-weekly rifampicin. Postgrad Med J 1971; 47(553):727-47
  10. Ackroyd JF. The pathogenesis of thrombocytopenic purpura due to hypersensitivity to seclomid. Clin Sci (Lond) 1949; 7(3-4):249-85
  11. Aquinas M, Allan WG, Horsfall PA, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J 1972 25; 1(5803):765-71.